Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial Noah Stansfield

Published Date: 02 Feb 2026

With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot